{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:14:29Z","timestamp":1790885669835,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072653"],"award-info":[{"award-number":["82072653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602035"],"award-info":[{"award-number":["81602035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472228"],"award-info":[{"award-number":["81472228"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Health Commission: Shanghai Outstanding Youth Specialist Training Programme","award":["Q2017-059"],"award-info":[{"award-number":["Q2017-059"]}]},{"name":"Clinical Science and Technology Innovation Project of Shanghai","award":["SHDC12016104"],"award-info":[{"award-number":["SHDC12016104"]}]},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive","award":["17DZ2252600"],"award-info":[{"award-number":["17DZ2252600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination of conventional transarterial chemoembolization (cTACE) and systemic therapy has the potential to treat chemotherapy-refractory unresectable colorectal liver metastases (CRLMs). This study aimed to compare survival after this combined treatment versus systemic chemotherapy alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre RCT included patients with unresectable CRLMs that progressed after first-line treatment. Patients were randomized on a 1\u00a0:\u00a01 basis to either systemic chemotherapy with or without cTACE, without further stratification. The primary outcome was progression-free survival (PFS). Secondary outcomes were overall response rate, disease control rate, conversion rate to liver resection, overall survival, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 180 patients recruited, 168 were randomized. Eighty-five patients in arm A received systemic chemotherapy plus cTACE and 83 in arm B received systemic chemotherapy alone. Median PFS was longer in arm A than B (6.7 versus 3.8 months; hazard ratio (HR) 0.67, 95 per cent c.i. 0.49 to 0.91; P\u2009=\u20090.009), but did not translate into prolonged median overall survival (18.4 versus 14.8 months; HR\u2009=\u20090.92, 0.62 to 1.36; P\u2009=\u20090.669). Overall response rates (20 versus 22 per cent; P\u2009=\u20090.788) and conversion rate to liver resection (18 versus 16 per cent; P\u2009=\u20090.730) were no different between arms A and B. The disease control rate was higher in arm A than arm B (67 versus 51 per cent; P\u2009=\u20090.030). No adverse event higher than grade 3 according to the Common Terminology Criteria for Adverse Events was observed during treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Systemic chemotherapy plus cTACE is a safe option as second-line treatment for unresectable colorectal liver metastases, with a modest effect on PFS. Registration number: NCT03783559 (http:\/\/www.clinicaltrials.gov).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znaa155","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:12:50Z","timestamp":1609474370000},"page":"373-379","source":"Crossref","is-referenced-by-count":16,"title":["Conventional transarterial chemoembolization combined with systemic therapy <i>versus<\/i> systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial"],"prefix":"10.1093","volume":"108","author":[{"given":"Y","family":"Liu","sequence":"first","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Chang","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wei","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Tang","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Chen","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Zhongshan Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ren","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-9301","authenticated-orcid":false,"given":"J","family":"Xu","sequence":"additional","affiliation":[{"name":"Colorectal Cancer Centre, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China"},{"name":"Shanghai Engineering Research Centre of Colorectal Cancer Minimally Invasive , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,21]]},"reference":[{"key":"2023063010550651200_znaa155-B1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/bjs.10457","article-title":"Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway","volume":"104","author":"Angelsen","year":"2017","journal-title":"Br J Surg"},{"key":"2023063010550651200_znaa155-B2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"2023063010550651200_znaa155-B3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bjs.11609","article-title":"Management of colorectal cancer metastases to the liver, lung or peritoneum suitable for curative intent: summary of NICE guidance","volume":"107","author":"Mohamed","year":"2020","journal-title":"Br J Surg"},{"key":"2023063010550651200_znaa155-B4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/ijc.28443","article-title":"Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period","volume":"134","author":"Gruber-Rouh","year":"2014","journal-title":"Int J Cancer"},{"key":"2023063010550651200_znaa155-B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023063010550651200_znaa155-B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000342047","article-title":"Oncological management of unresectable liver metastases","volume":"30","author":"Prenen","year":"2012","journal-title":"Dig Dis"},{"key":"2023063010550651200_znaa155-B7","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023063010550651200_znaa155-B8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/bjs.11283","article-title":"Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial","volume":"106","author":"Garlipp","year":"2019","journal-title":"Br J Surg"},{"key":"2023063010550651200_znaa155-B9","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.21873\/anticanres.13442","article-title":"Comparison of response and outcomes of drug-eluting bead chemoembolization (DEB-TACE) versus radioembolization (TARE) for patients with colorectal cancer liver metastases","volume":"39","author":"Mokkarala","year":"2019","journal-title":"Anticancer Res"},{"key":"2023063010550651200_znaa155-B10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s12885-019-5862-3","article-title":"Selective TACE with irinotecan-loaded 40 \u03bcm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study","volume":"19","author":"Tanaka","year":"2019","journal-title":"BMC Cancer"},{"key":"2023063010550651200_znaa155-B11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s00261-020-02584-6","article-title":"Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis","volume":"45","author":"Ren","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"2023063010550651200_znaa155-B12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00423-015-1308-9","article-title":"Transarterial chemoembolization (TACE) for colorectal liver metastases\u2014current status and critical review","volume":"400","author":"Massmann","year":"2015","journal-title":"Langenbecks Arch Surg"},{"key":"2023063010550651200_znaa155-B13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/CAD.0000000000000690","article-title":"Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases","volume":"29","author":"Shao","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2023063010550651200_znaa155-B14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jvir.2012.10.014","article-title":"Chemoembolization for colorectal liver metastases after FOLFOX failure","volume":"24","author":"Clark","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"2023063010550651200_znaa155-B15","doi-asserted-by":"crossref","first-page":"C205","DOI":"10.4103\/0973-1482.200603","article-title":"The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases","volume":"12","author":"Yu","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"2023063010550651200_znaa155-B16","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"key":"2023063010550651200_znaa155-B17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdp549","article-title":"Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic\/pharmacodynamic phase I dose-escalation study","volume":"21","author":"Tabernero","year":"2010","journal-title":"Ann Oncol"},{"key":"2023063010550651200_znaa155-B18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023063010550651200_znaa155-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2023063010550651200_znaa155-B20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2023063010550651200_znaa155-B21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"2023063010550651200_znaa155-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.2007-0142","article-title":"Expanding criteria for resectability of colorectal liver metastases","volume":"13","author":"Pawlik","year":"2008","journal-title":"Oncologist"},{"key":"2023063010550651200_znaa155-B23","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/gut.2006.098053","article-title":"Guidelines for resection of colorectal cancer liver metastases","volume":"55","author":"Garden","year":"2006","journal-title":"Gut"},{"key":"2023063010550651200_znaa155-B24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1245\/s10434-006-9023-y","article-title":"Selection of patients for resection of hepatic colorectal metastases: expert consensus statement","volume":"13","author":"Charnsangavej","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2023063010550651200_znaa155-B25","first-page":"461","article-title":"Common terminology criteria for adverse events v3.0 (CTCAE)","volume":"42","author":"Hamashige","year":"2008","journal-title":"Principles Pract Clin Trial Med"},{"key":"2023063010550651200_znaa155-B26","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023063010550651200_znaa155-B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaoncol.2018.4465","article-title":"Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 randomized clinical trial","volume":"5","author":"Bennouna","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023063010550651200_znaa155-B28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cncr.25387","article-title":"Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol","volume":"117","author":"Albert","year":"2011","journal-title":"Cancer"},{"key":"2023063010550651200_znaa155-B29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1477-7819-7-80","article-title":"Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report","volume":"7","author":"Martin","year":"2009","journal-title":"World J Surg Oncol"},{"key":"2023063010550651200_znaa155-B30","first-page":"4581","article-title":"Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead\u00ae, drug-eluting bead loaded with irinotecan: results of a phase II clinical study","volume":"31","author":"Aliberti","year":"2011","journal-title":"Anticancer Res"},{"key":"2023063010550651200_znaa155-B31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3892\/ijo.2012.1572","article-title":"First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI)","volume":"41","author":"Eichler","year":"2012","journal-title":"Int J Oncol"},{"key":"2023063010550651200_znaa155-B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023063010550651200_znaa155-B33","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023063010550651200_znaa155-B34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023063010550651200_znaa155-B35","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/4\/373\/50745971\/znaa155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/4\/373\/50745971\/znaa155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:58:07Z","timestamp":1688122687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/108\/4\/373\/6145853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,21]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,21]]},"published-print":{"date-parts":[[2021,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znaa155","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,21]]}}}